menu
    • menu
    [{"orgOrder":0,"company":"Ginkgo Bioworks","sponsor":"Moderna Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Oligonucleotide","year":"2020","type":"Collaboration","leadProduct":"Inapplicable","moa":"||SARS-CoV-2 S","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Ginkgo Bioworks","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Ginkgo Bioworks \/ Moderna Therapeutics","highestDevelopmentStatusID":"6","companyTruncated":"Ginkgo Bioworks \/ Moderna Therapeutics"},{"orgOrder":0,"company":"Ginkgo Bioworks","sponsor":"SaponiQx","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2021","type":"Collaboration","leadProduct":"Inapplicable","moa":"||Undisclosed","graph1":"Oncology","graph2":"Discovery Platform","graph3":"Ginkgo Bioworks","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Ginkgo Bioworks \/ Ginkgo Bioworks","highestDevelopmentStatusID":"3","companyTruncated":"Ginkgo Bioworks \/ Ginkgo Bioworks"},{"orgOrder":0,"company":"Ginkgo Bioworks","sponsor":"Circularis Biotechnologies","pharmaFlowCategory":"D","therapeuticArea":"Technology","country":"U.S.A","productType":"Undisclosed","year":"2022","type":"Acquisition","leadProduct":"Inapplicable","moa":"||Undisclosed","graph1":"Technology","graph2":"Discovery Platform","graph3":"Ginkgo Bioworks","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Technology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Ginkgo Bioworks \/ Ginkgo Bioworks","highestDevelopmentStatusID":"3","companyTruncated":"Ginkgo Bioworks \/ Ginkgo Bioworks"},{"orgOrder":0,"company":"Ginkgo Bioworks","sponsor":"Microba Life Sciences","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"AUSTRALIA","productType":"Undisclosed","year":"2022","type":"Partnership","leadProduct":"Inapplicable","moa":"||Undisclosed","graph1":"Immunology","graph2":"Discovery","graph3":"Ginkgo Bioworks","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Ginkgo Bioworks \/ Ginkgo Bioworks","highestDevelopmentStatusID":"2","companyTruncated":"Ginkgo Bioworks \/ Ginkgo Bioworks"},{"orgOrder":0,"company":"Ginkgo Bioworks","sponsor":"Esperovax","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2023","type":"Partnership","leadProduct":"Inapplicable","moa":"||Undisclosed","graph1":"Oncology","graph2":"Discovery","graph3":"Ginkgo Bioworks","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Ginkgo Bioworks \/ Ginkgo Bioworks","highestDevelopmentStatusID":"2","companyTruncated":"Ginkgo Bioworks \/ Ginkgo Bioworks"},{"orgOrder":0,"company":"Ginkgo Bioworks","sponsor":"Prokarium","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2023","type":"Partnership","leadProduct":"Inapplicable","moa":"||Undisclosed","graph1":"Oncology","graph2":"Discovery","graph3":"Ginkgo Bioworks","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Ginkgo Bioworks \/ Ginkgo Bioworks","highestDevelopmentStatusID":"2","companyTruncated":"Ginkgo Bioworks \/ Ginkgo Bioworks"},{"orgOrder":0,"company":"Ginkgo Bioworks","sponsor":"Modulus Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2024","type":"Acquisition","leadProduct":"Inapplicable","moa":"||Undisclosed","graph1":"Oncology","graph2":"Discovery","graph3":"Ginkgo Bioworks","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Ginkgo Bioworks \/ Ginkgo Bioworks","highestDevelopmentStatusID":"2","companyTruncated":"Ginkgo Bioworks \/ Ginkgo Bioworks"},{"orgOrder":0,"company":"Ginkgo Bioworks","sponsor":"Boehringer Ingelheim GmbH","pharmaFlowCategory":"D","therapeuticArea":"Technology","country":"U.S.A","productType":"Undisclosed","year":"2023","type":"Partnership","leadProduct":"Inapplicable","moa":"||Undisclosed","graph1":"Technology","graph2":"Discovery","graph3":"Ginkgo Bioworks","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Technology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Ginkgo Bioworks \/ Boehringer Ingelheim GmbH","highestDevelopmentStatusID":"2","companyTruncated":"Ginkgo Bioworks \/ Boehringer Ingelheim GmbH"},{"orgOrder":0,"company":"Ginkgo Bioworks","sponsor":"Pfizer Inc","pharmaFlowCategory":"D","therapeuticArea":"Technology","country":"U.S.A","productType":"Undisclosed","year":"2023","type":"Collaboration","leadProduct":"Inapplicable","moa":"||Undisclosed","graph1":"Technology","graph2":"Discovery","graph3":"Ginkgo Bioworks","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Technology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Ginkgo Bioworks \/ Pfizer Inc","highestDevelopmentStatusID":"2","companyTruncated":"Ginkgo Bioworks \/ Pfizer Inc"},{"orgOrder":0,"company":"Ginkgo Bioworks","sponsor":"Cronos Group","pharmaFlowCategory":"D","therapeuticArea":"Nutrition and Weight Loss","country":"CANADA","productType":"Undisclosed","year":"2022","type":"Partnership","leadProduct":"Inapplicable","moa":"||CBR","graph1":"Nutrition and Weight Loss","graph2":"Undisclosed","graph3":"Ginkgo Bioworks","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Oral","sponsorNew":"Ginkgo Bioworks \/ Ginkgo Bioworks","highestDevelopmentStatusID":"1","companyTruncated":"Ginkgo Bioworks \/ Ginkgo Bioworks"},{"orgOrder":0,"company":"Ginkgo Bioworks","sponsor":"Biogen","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Undisclosed","year":"2021","type":"Collaboration","leadProduct":"Inapplicable","moa":"||Undisclosed","graph1":"Neurology","graph2":"Undisclosed","graph3":"Ginkgo Bioworks","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Ginkgo Bioworks \/ Biogen","highestDevelopmentStatusID":"1","companyTruncated":"Ginkgo Bioworks \/ Biogen"},{"orgOrder":0,"company":"Ginkgo Bioworks","sponsor":"Synlogic","pharmaFlowCategory":"DU","therapeuticArea":"Rheumatology","country":"U.S.A","productType":"Probiotic","year":"2022","type":"Inapplicable","leadProduct":"Inapplicable","moa":"||Undisclosed","graph1":"Rheumatology","graph2":"IND Enabling","graph3":"Ginkgo Bioworks","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Rheumatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Ginkgo Bioworks \/ Ginkgo Bioworks","highestDevelopmentStatusID":"5","companyTruncated":"Ginkgo Bioworks \/ Ginkgo Bioworks"},{"orgOrder":0,"company":"Ginkgo Bioworks","sponsor":"Prokarium","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2023","type":"Financing","leadProduct":"Inapplicable","moa":"||Undisclosed","graph1":"Oncology","graph2":"IND Enabling","graph3":"Ginkgo Bioworks","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Ginkgo Bioworks \/ Ginkgo Bioworks","highestDevelopmentStatusID":"5","companyTruncated":"Ginkgo Bioworks \/ Ginkgo Bioworks"},{"orgOrder":0,"company":"Ginkgo Bioworks","sponsor":"Universal Cells","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2025","type":"Collaboration","leadProduct":"Inapplicable","moa":"||Undisclosed","graph1":"Oncology","graph2":"Discovery Platform","graph3":"Ginkgo Bioworks","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Ginkgo Bioworks \/ Universal Cells","highestDevelopmentStatusID":"3","companyTruncated":"Ginkgo Bioworks \/ Universal Cells"},{"orgOrder":0,"company":"Ginkgo Bioworks","sponsor":"StrideBio","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Undisclosed","year":"2023","type":"Acquisition","leadProduct":"Inapplicable","moa":"||Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Discovery","graph3":"Ginkgo Bioworks","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Ginkgo Bioworks \/ Ginkgo Bioworks","highestDevelopmentStatusID":"2","companyTruncated":"Ginkgo Bioworks \/ Ginkgo Bioworks"},{"orgOrder":0,"company":"Ginkgo Bioworks","sponsor":"Novo Nordisk","pharmaFlowCategory":"D","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Undisclosed","year":"2024","type":"Expanded Collaboration","leadProduct":"Inapplicable","moa":"||Undisclosed","graph1":"Endocrinology","graph2":"Discovery","graph3":"Ginkgo Bioworks","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Ginkgo Bioworks \/ Novo Nordisk","highestDevelopmentStatusID":"2","companyTruncated":"Ginkgo Bioworks \/ Novo Nordisk"},{"orgOrder":0,"company":"Ginkgo Bioworks","sponsor":"Novo Nordisk","pharmaFlowCategory":"D","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Undisclosed","year":"2022","type":"Collaboration","leadProduct":"Inapplicable","moa":"||Undisclosed","graph1":"Endocrinology","graph2":"Discovery","graph3":"Ginkgo Bioworks","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Ginkgo Bioworks \/ Novo Nordisk","highestDevelopmentStatusID":"2","companyTruncated":"Ginkgo Bioworks \/ Novo Nordisk"},{"orgOrder":0,"company":"Ginkgo Bioworks","sponsor":"Bill & Melinda Gates Foundation","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Undisclosed","year":"2023","type":"Funding","leadProduct":"Inapplicable","moa":"||Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Discovery","graph3":"Ginkgo Bioworks","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Implant","sponsorNew":"Ginkgo Bioworks \/ Bill & Melinda Gates Foundation","highestDevelopmentStatusID":"2","companyTruncated":"Ginkgo Bioworks \/ Bill & Melinda Gates Foundation"}]

    Find Clinical Drug Pipeline Developments & Deals by Ginkgo Bioworks

    Menu

    Ginkgo Bioworks

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Ginkgo Bioworks

                            U.S.A arrow
                            EPSC
                            Not Confirmed

                            Ginkgo Bioworks

                            U.S.A arrow
                            EPSC
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Undisclosed,Inapplicable

                            Therapeutic Area : Oncology

                            Study Phase : Discovery Platform

                            Sponsor : Universal Cells

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            DEALS_DEV arrow-down

                            Ginkgo Bioworks Partners with Universal Cells to Advance iPSC-Derived Therapies

                            Details : This collaboration underscores Ginkgo's capacity to deploy high-throughput biological approaches to tackle the complex challenge set associated with development of therapies targeting solid tumors.

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : Undisclosed

                            January 13, 2025

                            Lead Product(s) : Undisclosed,Inapplicable

                            Therapeutic Area : Oncology

                            Highest Development Status : Discovery Platform

                            Sponsor : Universal Cells

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Ginkgo Bioworks

                            U.S.A arrow
                            EPSC
                            Not Confirmed

                            Ginkgo Bioworks

                            U.S.A arrow
                            EPSC
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Undisclosed,Inapplicable

                            Therapeutic Area : Endocrinology

                            Study Phase : Discovery

                            Sponsor : Novo Nordisk

                            Deal Size : Undisclosed

                            Deal Type : Expanded Collaboration

                            DEALS_DEV arrow-down

                            Ginkgo Bioworks and Novo Nordisk Expand Alliance to Collaborate Across R&D Value Chain

                            Details : The partnership aims to enhance the manufacturing of Novo's medicines for serious chronic diseases, including diabetes and obesity, leveraging Ginkgo's synthetic biology platform for new methods.

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : Undisclosed

                            October 04, 2024

                            Lead Product(s) : Undisclosed,Inapplicable

                            Therapeutic Area : Endocrinology

                            Highest Development Status : Discovery

                            Sponsor : Novo Nordisk

                            Deal Size : Undisclosed

                            Deal Type : Expanded Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Ginkgo Bioworks

                            U.S.A arrow
                            EPSC
                            Not Confirmed

                            Ginkgo Bioworks

                            U.S.A arrow
                            EPSC
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Undisclosed,Inapplicable

                            Therapeutic Area : Oncology

                            Study Phase : Discovery

                            Recipient : Modulus Therapeutics

                            Deal Size : Undisclosed

                            Deal Type : Acquisition

                            DEALS_DEV arrow-down

                            Ginkgo Bioworks Acquires Modulus Cell Therapy Platform Assets

                            Details : Through the acquisition, Ginkgo will get access to the Modulus cell therapy platform assets, including their chimeric antigen receptor and switch receptor libraries for solid tumors, autoimmune, etc.

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : Undisclosed

                            February 04, 2024

                            Lead Product(s) : Undisclosed,Inapplicable

                            Therapeutic Area : Oncology

                            Highest Development Status : Discovery

                            Recipient : Modulus Therapeutics

                            Deal Size : Undisclosed

                            Deal Type : Acquisition

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Ginkgo Bioworks

                            U.S.A arrow
                            EPSC
                            Not Confirmed

                            Ginkgo Bioworks

                            U.S.A arrow
                            EPSC
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Undisclosed,Inapplicable

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Discovery

                            Sponsor : Bill & Melinda Gates Foundation

                            Deal Size : Undisclosed

                            Deal Type : Funding

                            DEALS_DEV arrow-down

                            Ginkgo Bioworks Receives Grant to Develop Innovative Live Cell Delivery Platform of Antibody Therapeutics for ...

                            Details : The financing will be used to develop a novel live cell therapeutic that can produce antibodies to fight human immunodeficiency virus (HIV) and/or malaria directly in the body.

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : Undisclosed

                            December 13, 2023

                            Lead Product(s) : Undisclosed,Inapplicable

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Discovery

                            Sponsor : Bill & Melinda Gates Foundation

                            Deal Size : Undisclosed

                            Deal Type : Funding

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Ginkgo Bioworks

                            U.S.A arrow
                            EPSC
                            Not Confirmed

                            Ginkgo Bioworks

                            U.S.A arrow
                            EPSC
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Undisclosed,Inapplicable

                            Therapeutic Area : Technology

                            Study Phase : Discovery

                            Sponsor : Pfizer Inc

                            Deal Size : $331.0 million

                            Deal Type : Collaboration

                            DEALS_DEV arrow-down

                            Ginkgo Bioworks Announces Multi-Target RNA Discovery Collaboration with Pfizer

                            Details : Under the collaboration, Pfizer will leverage Ginkgo's proprietary RNA technology to advance the discovery and development of novel RNA molecules across priority research areas.

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : Undisclosed

                            September 27, 2023

                            Lead Product(s) : Undisclosed,Inapplicable

                            Therapeutic Area : Technology

                            Highest Development Status : Discovery

                            Sponsor : Pfizer Inc

                            Deal Size : $331.0 million

                            Deal Type : Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            Ginkgo Bioworks

                            U.S.A arrow
                            EPSC
                            Not Confirmed

                            Ginkgo Bioworks

                            U.S.A arrow
                            EPSC
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Undisclosed,Inapplicable

                            Therapeutic Area : Oncology

                            Study Phase : IND Enabling

                            Recipient : Prokarium

                            Deal Size : $30.0 million

                            Deal Type : Financing

                            DEALS_DEV arrow-down

                            Prokarium Announces $30 Million Financing to Deliver Lead Program into Clinic and Build Novel Therapeutic Plat...

                            Details : Proceeds will support clinical development of the Company’s lead oncology candidate in non-muscle invasive bladder cancer and accelerate platform discovery.

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : Undisclosed

                            September 02, 2023

                            Lead Product(s) : Undisclosed,Inapplicable

                            Therapeutic Area : Oncology

                            Highest Development Status : IND Enabling

                            Recipient : Prokarium

                            Deal Size : $30.0 million

                            Deal Type : Financing

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            Ginkgo Bioworks

                            U.S.A arrow
                            EPSC
                            Not Confirmed

                            Ginkgo Bioworks

                            U.S.A arrow
                            EPSC
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Undisclosed,Inapplicable

                            Therapeutic Area : Oncology

                            Study Phase : Discovery

                            Recipient : Prokarium

                            Deal Size : Undisclosed

                            Deal Type : Partnership

                            DEALS_DEV arrow-down

                            Prokarium and Ginkgo Bioworks Announce Partnership to Discover Multiple Targets for RNA Therapeutics and Immun...

                            Details : Bactofection, the process of transferring genetic material into a mammalian cell via a bacterium, is an alternative gene delivery system that could deliver therapeutic agents to a patient in RNA-based therapy.

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : Undisclosed

                            September 01, 2023

                            Lead Product(s) : Undisclosed,Inapplicable

                            Therapeutic Area : Oncology

                            Highest Development Status : Discovery

                            Recipient : Prokarium

                            Deal Size : Undisclosed

                            Deal Type : Partnership

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            08

                            Ginkgo Bioworks

                            U.S.A arrow
                            EPSC
                            Not Confirmed

                            Ginkgo Bioworks

                            U.S.A arrow
                            EPSC
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Undisclosed,Inapplicable

                            Therapeutic Area : Technology

                            Study Phase : Discovery

                            Sponsor : Boehringer Ingelheim GmbH

                            Deal Size : $406.0 million

                            Deal Type : Partnership

                            DEALS_DEV arrow-down

                            Ginkgo Bioworks Partners with Boehringer Ingelheim to Develop Breakthrough Therapies for Hard-to-Treat Disease...

                            Details : The companies will leverage Ginkgo's natural product discovery capabilities to accelerate the discovery and development of novel therapeutic molecules to address diseases with high unmet patient needs that are out of reach of conventional drug discovery.

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : Undisclosed

                            August 05, 2023

                            Lead Product(s) : Undisclosed,Inapplicable

                            Therapeutic Area : Technology

                            Highest Development Status : Discovery

                            Sponsor : Boehringer Ingelheim GmbH

                            Deal Size : $406.0 million

                            Deal Type : Partnership

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            09

                            Ginkgo Bioworks

                            U.S.A arrow
                            EPSC
                            Not Confirmed

                            Ginkgo Bioworks

                            U.S.A arrow
                            EPSC
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Undisclosed,Inapplicable

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Study Phase : Discovery

                            Recipient : StrideBio

                            Deal Size : Undisclosed

                            Deal Type : Acquisition

                            DEALS_DEV arrow-down

                            Ginkgo Bioworks Strengthens End-to-End R&D Capabilities in Gene Therapy through Acquisition of StrideBio's AAV...

                            Details : The addition of StrideBio's structure-guided AAV engineering capabilities combined with Ginkgo's already extensive assets make Ginkgo a unique one-stop shop capable of providing R&D services for gene therapy manufacturing across capsid, payload, and cell...

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : Undisclosed

                            May 04, 2023

                            Lead Product(s) : Undisclosed,Inapplicable

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Highest Development Status : Discovery

                            Recipient : StrideBio

                            Deal Size : Undisclosed

                            Deal Type : Acquisition

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            10

                            Ginkgo Bioworks

                            U.S.A arrow
                            EPSC
                            Not Confirmed

                            Ginkgo Bioworks

                            U.S.A arrow
                            EPSC
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Undisclosed,Inapplicable

                            Therapeutic Area : Oncology

                            Study Phase : Discovery

                            Recipient : Esperovax

                            Deal Size : Undisclosed

                            Deal Type : Partnership

                            DEALS_DEV arrow-down

                            Esperovax and Ginkgo Bioworks Announce Partnership to Develop Circular RNA-based Therapeutics

                            Details : CircRNAs (circular RNA based therapy) represent an emerging, powerful mechanism for delivering therapeutics and vaccines due to their protein-coding potential and improved stability in comparison to their linear mRNA counterparts.

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : Undisclosed

                            May 01, 2023

                            Lead Product(s) : Undisclosed,Inapplicable

                            Therapeutic Area : Oncology

                            Highest Development Status : Discovery

                            Recipient : Esperovax

                            Deal Size : Undisclosed

                            Deal Type : Partnership

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth